
In a study of 564 patients with localized kidney cancer, a study found that patients with a subtype called sRCC (sarcomatoid renal cell carcinoma) had worse cancer-specific survival (CSS) compared to those with grade-4 non-sRCC. Even at lower stages, sRCC had poorer CSS, with negative predictors including positive surgical margins, higher stage, minimally invasive surgery, and non-clear cell histology. An external validation from the ASSURE trial confirmed these findings. This study emphasizes the aggressiveness of localized sRCC and suggests the need for vigilant monitoring and potential inclusion in adjuvant therapy trials for even early-stage patients.
Like
Save
Share